The South Korea anti-fungal drugs market size stood at around USD 134.3 million in 2019 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx% during the forecast period.
Anti-fungal drugs are used to cure fungal infections caused by unhygienic and damp environment. Fungal infections are invasion of epithelial tissue by microscopic organisms. Systemic fungal infections like candidiasis, mucormycosis are caused by inhalation of fungal spores. Most of the fungal infections and lesions are non-lethal but highly uncomfortable to live with. Commonly occurring fungal infections are accountable for the rise of antifungal drugs market.
According to data from the Korea Centres for Disease Control and Prevention, the number of patients with fungal infections is increasing year by year and the mortality rate from fungal infections is 22.4%.
Major factors driving the market are rising awareness of fungal infections with increasing incidence of antifungal infections. Furthermore, development in pharmaceutical industry and rising popularity of over-the-counter antifungal drugs for dermal infections are vastly responsible for increasing the market size.
Growing anti-fungal drug resistance, their side effects and presence of counterfeit drugs are the restraints for the market.